Iron Deficiency Is Common after Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis [0.03%]
溃疡性结肠炎行回肠储袋肛管吻合术患者铁缺乏十分常见
Ishaan Dharia,Taqwa Ahmed,Michael Plietz et al.
Ishaan Dharia et al.
Background: Micronutrient deficiencies may occur after restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis (UC), largely due to malabsorption and/or pouch inflamm...
Clinical Background Factors as Predictors of the Efficacy of 5-Aminosalicylic Acid Suppositories in Patients with Ulcerative Colitis [0.03%]
预测溃疡性结肠炎患者5-氨基水杨酸栓剂疗效的临床基线因素
Kazuhiko Uchiyama,Tomohisa Takagi,Katsura Mizushima et al.
Kazuhiko Uchiyama et al.
Introduction: Although the efficacy of 5-aminosalicylic acid (ASA) suppositories for ulcerative colitis (UC) has been reported in many studies, many studies have also described poor adherence to 5-ASA suppository regimens...
Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey [0.03%]
关于溃疡性结肠炎患者的药物配方偏好的欧洲调查研究——轻度及中度患者
Xavier Hébuterne,Stephan R Vavricka,Helen C Thorne et al.
Xavier Hébuterne et al.
Introduction: Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medicat...
A Systematic Review of Self-Management Interventions for Patients with Inflammatory Bowel Disease [0.03%]
炎症性肠病患者的自我管理干预的系统评价
Masami Iizawa,Lisa Hirose,Maya Nunotani et al.
Masami Iizawa et al.
Introduction: Previous studies have reported the effectiveness of inflammatory bowel disease (IBD) self-management. However, it is unclear which types of self-management interventions are effective. We conducted a systema...
Construction of an Explanatory Model for Quality of Life in Outpatients with Ulcerative Colitis [0.03%]
溃疡性结肠炎门诊患者的生存质量解释模型的构建
Miho Takahashi,Maya Nunotani,Nobuo Aoyama
Miho Takahashi
Introduction: To date, no studies have reported explanatory models of health-related quality of life (HRQoL) in patients with ulcerative colitis. Therefore, this study aimed to examine HRQoL and its related factors in out...
Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn's Disease [0.03%]
血清富亮氨酸α2甘露糖蛋白作为克罗恩病小肠病变生物标志物的最优应用研究
Kunio Asonuma,Taku Kobayashi,Nao Kikkawa et al.
Kunio Asonuma et al.
Introduction: A large proportion of small bowel lesions in Crohn's disease (CD) may exist beyond the reach of ileocolonoscopy and there is no gold standard imaging modality to screen them, suggesting the need for optimal ...
Smoking Is Not an Independent Risk Factor for Surgery in Patients with Crohn's Disease on Biologic Therapy [0.03%]
生物制剂治疗克罗恩病患者手术中吸烟不是独立的风险因素
Saleem M Halablab,Ayman Alrazim,Christian Sadaka et al.
Saleem M Halablab et al.
Introduction: The development and course of inflammatory bowel disease appear to be influenced by environmental factors. Particularly, smoking has been shown to assume a harmful role in Crohn's disease (CD) and a protecti...
A Regional Survey of Awareness of Inflammatory Bowel Disease among the Saudi Population [0.03%]
沙特阿拉伯人口对炎症性肠病认知的地区性调查
Yaser Khalid Meeralam,Adnan Al Zanabgi,Mahmoud Mosli et al.
Yaser Khalid Meeralam et al.
Introduction: Inflammatory bowel disease (IBD) is common worldwide, including the gulf region. Early diagnosis of IBD can improve patients' outcomes. However, early diagnosis is dependent on patients' awareness of the dis...
Akira Andoh,Atsushi Nishida
Akira Andoh
Background: Intestinal fibrosis in Crohn's disease (CD) is considered to be irreversible and induces persistent luminal narrowing and strictures. In the past decades, substantial advances have been made in the understandi...
Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan [0.03%]
戈利木单抗治疗溃疡性结肠炎有效性和安全性：日本上市后观察52周结果
Shiro Nakamura,Teita Asano,Yoshihito Tanaka et al.
Shiro Nakamura et al.
Introduction: Real-world evidence for the effectiveness and safety of golimumab (GLM) in patients with ulcerative colitis (UC) is limited. The aim of this study was to investigate the 52-week effectiveness and safety of G...